DDInter856 DDInter286
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Caplacizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Caplacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Caplacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Caplacizumab {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Caplacizumab {u} may lead to a major life threatening interaction when taken with {v} Prasugrel
Caplacizumab may cause a minor interaction that can limit clinical effects when taken with Turmeric
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Caplacizumab may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Caplacizumab may lead to a major life threatening interaction when taken with Prasugrel